Adagio Medical Holdings, Inc.
Adagio Medical Holdings develops and commercializes catheter-based devices for treating cardiac arrhythmias, with an initial focus on ventricular tachycardia. Its products use Ultra-Low Temperature Ablation technology to create lesions in heart tissue without irrigation. The vCLAS Cryoablation System combines a ventricular catheter with an ablation console and has European CE Mark approval. Adagio is also developing the next-generation vCLAS ULTRA system and Pulsed Field Cryoablation, which combines its temperature-based technology with pulsed field ablation. The company’s customers are not specified, but its products are designed for physicians performing cardiac ablation procedures. Adagio seeks to make money by commercializing its medical devices. It is headquartered in Laguna Hills, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ADGM in the last 30 days.
See all $ADGM insider activity →Adagio Medical (ADGM) treated 22 patients with its vCLAS Ultra system in a study across the U.S. and Canada. The FULCRUM-VT trial, evaluating the system's safety and effectiveness, enrolled 209 patients. Doctors reported over 60% reduction in ablation times. The company is also reviewing strategic alternatives and submitted a PMA application for its first-generation system to the FDA in May 2026.
Adagio Medical Holdings, Inc. (ADGM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On October 23, 2026, Adagio Medical Holdings, Inc.’s (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). The stockholders considered one proposal which is described in more detail in the Co
Adagio Medical Holdings, Inc. (ADGM) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. As previously disclosed in Adagio Medical Holdings, Inc.’s (the “Company”) Current Report on Form 8-K filed on September 23, 2026, in connection with its process to explore strategic alternatives, the Company notified the holders
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ADGM (Adagio Medical Holdings, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ADGM coverage spans technology, corporate actions and regulation.
The new patient data demonstrates procedural time reductions and successful enrollment, indicating progress toward regulatory clearance and commercial rollout.
The approved reverse split may pressure the stock as the share count will be reduced, potentially widening the price per share.
Adagio Medical Holdings, Inc. (ADGM) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. As previously disclosed in Adagio Medical Holdings, Inc.’s (the “Company”) Current Report on Form 8-K filed on September 23, 2026, in connection with its process to explore strategic alternatives, the Company notified the holders
The announcement may trigger speculation on a sale or partnership, potentially increasing volatility.
Positive early clinical data may boost investor confidence and drive short-term price appreciation.
AlphAI scores every news story that mentions ADGM with an AI model for sentiment and relevance, and aggregates insider trades from Adagio Medical Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Adagio Medical (ADGM) treated 22 patients with its vCLAS Ultra system in a study across the U.S. and Canada. The FULCRUM-VT trial, evaluating the system's safety and effectiveness, enrolled 209 patients. Doctors reported over 60% reduction in ablation times. The company is also reviewing strategic alternatives and submitted a PMA application for its first-generation system to the FDA in May 2026.
Adagio Medical Holdings, Inc. (ADGM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On October 23, 2026, Adagio Medical Holdings, Inc.’s (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). The stockholders considered one proposal which is described in more detail in the Co
Adagio Medical Holdings, Inc. (ADGM) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. As previously disclosed in Adagio Medical Holdings, Inc.’s (the “Company”) Current Report on Form 8-K filed on September 23, 2026, in connection with its process to explore strategic alternatives, the Company notified the holders
Adagio Medical Holdings, Inc. (ADGM) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Adagio Medical Announces Strategic Review Process to Maximize Shareholder Value Company Continues to Advance PMA Application for vCLAS Ventricular Ablation System While Board Evaluates Full Range of Strategic Options LAGUNA HILLS, CA, September 23, 2026 – Adagio
Adagio Medical announced study results for its vClas Ultra cryoablation system, with the first patient treated by Dr. Roderick Tung. The study aims to support FDA approval for the first-generation device. Shares of Adagio (ADGM) were trading at 47 cents with a market cap of $10.6 million.
Adagio Medical (ADGM) announced the first patient treated in its IDE study for the next-gen vCLAS Ultra System, designed for ventricular tachycardia (VT). The study aims to support a PMA supplement for the FDA. The system showed improved maneuverability and reduced ablation time in pre-clinical data. The company is focused on demonstrating the system's potential for faster, more efficient VT ablation procedures.
Adagio Medical Holdings, Inc. (ADGM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Adagio Medical Reports Second Quarter 2026 Results LAGUNA HILLS, CA, August 11, 2026 – Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today anno
Adagio Medical (ADGM) shares rose 21.6% Monday and jumped 22% after hours, after the company said its next-generation vCLAS Ultra ULTA system treated its first patient at the University of Pennsylvania. Adagio also said the FDA approved expanding its FULCRUM-VT IDE trial for the new system and expects first-generation ULTA FDA approval soon.
Adagio Medical Holdings Inc. said it treated the first patient with its next-generation vCLAS Ultra low-temperature ablation system. The company claims it can reach -170°C and cut ablation time by 50% to 75%, shortening procedures by up to 30 minutes versus the prior system. Adagio noted the FDA granted IDE approval in April to expand its FULCRUM-VT trial. Shares rose 19% to 45 cents.
Adagio Medical Holdings, Inc. (ADGM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0002006986 0002006986 2026-06-16 2026-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
